Tangji Medical key facts
as of Oct 2026- Development and manufacturer of stent medical devices designed for the treatment of metabolic diseases.
- Tangji Medical is valued at approximately $185.4M as of Oct 2026 (last reported valuation).
- It has raised $44.0M; the latest was IPO in Feb 2026.
- Notable investors include Baidu Ventures, Proxima Ventures (China), Hangzhou Hi-Tech Financial Investment Group, Wuxi Guolian Development (Group), Guanghua Kaiyuan Capital — 18 tracked in total.
- Status: In IPO Registration.
Tangji Medical's last reported valuation, Nov 2025. Nothing priced has surfaced since.
- ·The complete investor list: 18 names
- ·Watch Tangji Medical: the Monday email on marks, rounds and moves
Tangji Medical funding rounds
No funding rounds for Tangji Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Tangji Medical
18+Membership and data by Private Market View
Tangji Medical valuation
Tangji Medical's last reported valuation was $185 million in Nov 2025. No priced round, secondary trade or fund mark has surfaced since.
Tangji Medical investors
18 investors are on record for Tangji Medical, including Baidu Ventures, Proxima Ventures (China), Hangzhou Hi-Tech Financial Investment Group and Wuxi Guolian Development (Group).
About Tangji Medical
Development and manufacturer of stent medical devices designed for the treatment of metabolic diseases. The company's main products include gastric bypass stent system and related stent devices, enabling patients to be relieved from metabolic diseases.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2016
- Employees
- 128
- Website
- tangjimed.com/
- Ownership
- In IPO Registration
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.